Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and ...

Shares of Vor Bio (Nasdaq: NASDAQ:VOR) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a ...

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% of ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.

China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after RemeGen revealed the success of a China phase 3 trial ...

Insiders have been trading these 5 stocks: (($FITB)), (($HEI)), (($TDG)), (($CYTK)) and (($VOR)). Here is a breakdown of their recent trades and ...

Vor Biopharma is developing novel cell therapies for AML, with trem-cel showing early promise in clinical trials but facing significant funding challenges. Trem-cel aims to enhance relapse-free ...